Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Théberge, J. Articles by Drost, D. J. Search for Related Content PubMed Citation Articles by Théberge, J. Articles by Drost, D. J. Schizophrenia Spectrum Disorders MRS Neurodegeneration

Glutamate and Glutamine in the Anterior Cingulate and Thalamus of Medicated Patients With Chronic Schizophrenia and Healthy Comparison Subjects Measured With 4.0-T Proton MRS

OBJECTIVE: This in vivo ¹H magnetic resonance spectroscopy study examined levels of glutamate, glutamine, and N-acetylaspartate in medicated patients with chronic schizophrenia. METHOD: Localized in vivo ¹H spectra were acquired at 4.0 T from the left anterior cingulate and thalamus of 21 patients with schizophrenia and 21 comparable healthy volunteers. RESULTS: Significantly lower levels of glutamine and glutamate were found in the left anterior cingulate cortex of patients with schizophrenia than in the healthy volunteers. For the schizophrenia patients, the glutamine level in the left thalamus was found to be higher than normal, and there was a significant negative correlation between N-acetylaspartate level and duration of positive symptoms. CONCLUSIONS: Since previous studies have found higher than normal levels of glutamine in the left anterior cingulate of never-treated patients, decreased levels of these metabolites in chronic patients could be related to neurodegeneration or the effects of chronic medication.

This article has been cited by other articles:

				H. van Wageningen, H. A. Jorgensen, K. Specht, and K. Hugdahl A 1H-MR Spectroscopy Study of Changes in Glutamate and Glutamine (Glx) Concentrations in Frontal Spectra after Administration of Memantine Cereb Cortex, July 15, 2009; (2009) bhp145v1. [Abstract] [Full Text] [PDF]

				J. THEBERGE, K. E. WILLIAMSON, N. AOYAMA, D. J. DROST, R. MANCHANDA, A. K. MALLA, S. NORTHCOTT, R. S. MENON, R. W. J. NEUFELD, N. RAJAKUMAR, et al. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia The British Journal of Psychiatry, October 1, 2007; 191(4): 325 - 334. [Abstract] [Full Text] [PDF]

				J. M. Stone, P. D. Morrison, and L. S. Pilowsky Review: Glutamate and dopamine dysregulation in schizophrenia a synthesis and selective review J Psychopharmacol, June 1, 2007; 21(4): 440 - 452. [Abstract] [PDF]

				L. M. Rowland, J. R. Bustillo, P. G. Mullins, R. E. Jung, R. Lenroot, E. Landgraf, R. Barrow, R. Yeo, J. Lauriello, and W. M. Brooks Effects of Ketamine on Anterior Cingulate Glutamate Metabolism in Healthy Humans: A 4-T Proton MRS Study Am J Psychiatry, February 1, 2005; 162(2): 394 - 396. [Abstract] [Full Text] [PDF]

				G. S. J. Rands, J. E. Jensen, J. Miller, P. C. Williamson, R. W. J. Neufeld, R. S. Menon, A. Malla, R. Manchanda, B. Schaefer, M. Densmore, et al. Memantine as a neuroprotective treatment in schizophrenia * Authors' reply The British Journal of Psychiatry, January 1, 2005; 186(1): 77 - 78. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2003 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us